Amgen reported a strong first quarter with a 22% year-over-year revenue increase driven by key products like Repatha and TEZSPIRE. Management maintained a positive outlook, highlighting robust pipeline advancements and successful integration of the Horizon acquisition despite increased operating expenses. The confident guidance for 2024 and ongoing strategic initiatives are likely to bolster investor sentiment in the short term.

[1]